Short‐ and Long‐Term Outcomes of Pericarditis, Myocarditis, and Myopericarditis in Patients With Malignancy on Immune Checkpoint Inhibitors
Journal of the American Heart Association · 2026
DOI: 10.1161/jaha.125.041163 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Heart Association, 2026. Verfasst von Ankit Agrawal und 12 weiteren Autor:innen. Beteiligte Einrichtung: Center for the Diagnosis and Treatment of Pericardial Diseases, Section of Cardiovascular Imaging, Department of Cardiovascular Medicine, Heart, Vasc…. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Myocarditis, Pericarditis, Neoplasms. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment but carry a risk of immune‐related adverse events, reported in 15% to 90% of the patients. ICI‐associated pericardial and myocardial disease has been increasingly recognized, yet data on outcomes remain limited. We aimed to use a large real‐world database to investigate the short‐ and long‐term outcomes of ICI‐associated pericarditis, myocarditis, and myopericarditis versus the non‐ICI cases.
Methods
We conducted a retrospective analysis using the TriNetX database to identify patients >18 years old on ICI and diagnosed with pericarditis, myocarditis, or myopericarditis within 1 year of initiation of therapy. The primary outcome assessed was all‐cause mortality, tamponade, constrictive pericarditis, and need for pericardiocentesis at 90‐day, 1‐year, and 5‐year follow‐up.
Results
A total of 3661, 226, and 46 patients were identified in matched cohorts of ICI‐induced pericarditis, myocarditis, and myopericarditis, respectively. One‐ and 5‐year mortality was greater for pericarditis (44.3% versus 37.3%; 54.3% versus 46.9%), myocarditis (38.9% versus 20.8%; 47.8% versus 34.3%), and myopericarditis (56.5% versus 28.3%; 63.0% versus 28.3%; all P ≤0.002). A multivariable Cox model showed increased ICI‐related mortality for pericarditis 1‐year hazard ratio [HR], 1.20 (95% CI, 1.12–1.29), 5‐year HR, 1.26 (95% CI, 1.18–1.35), myocarditis 90‐day HR, 1.82 (95% CI, 1.21–2.73), 1‐year HR, 2.04 (95% CI, 1.43–2.91), 5‐year HR, 1.64 (95% CI, 1.26–2.61), and myopericarditis 1‐year HR, 2.24 (95% CI, 1.15–4.37), and 5‐year HR, 2.78 (95% CI, 1.44–5.36), all with P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for the Diagnosis and Treatment of Pericardial Diseases, Section of Cardiovascular Imaging, Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute Cleveland Clinic Cleveland OH.
- Department of Medicine University Hospitals Cleveland OH.
ORCID-Profile: Ankit Agrawal, Akiva Rosenzveig, Danial Nasif, Jibran Ikram, Muhammad Ehsan, Muhammad Majid, Ashwin Kumar, Aro Daniela Arockiam, Allan L Klein
Zitieren
APA
Agrawal, A., Rosenzveig, A., Safdar, A., Nasif, D., Bhagat, U., Ikram, J., Ehsan, M., Majid, M., Kumar, A., Arockiam, A. D., Verma, B. R., Wajsberg, J., & Klein, A. L. (2026). Short‐ and Long‐Term Outcomes of Pericarditis, Myocarditis, and Myopericarditis in Patients With Malignancy on Immune Checkpoint Inhibitors. Journal of the American Heart Association. https://doi.org/10.1161/jaha.125.041163
Vancouver
Agrawal A, Rosenzveig A, Safdar A, Nasif D, Bhagat U, Ikram J, et al. Short‐ and Long‐Term Outcomes of Pericarditis, Myocarditis, and Myopericarditis in Patients With Malignancy on Immune Checkpoint Inhibitors. Journal of the American Heart Association. 2026. doi:10.1161/jaha.125.041163
BibTeX
@article{Agrawal2026,
author = {Agrawal, Ankit and Rosenzveig, Akiva and Safdar, Ahmad and Nasif, Danial and Bhagat, Umesh and Ikram, Jibran and Ehsan, Muhammad and Majid, Muhammad and Kumar, Ashwin and Arockiam, Aro Daniela and Verma, Beni R and Wajsberg, Julia and Klein, Allan L},
title = {Short‐ and Long‐Term Outcomes of Pericarditis, Myocarditis, and Myopericarditis in Patients With Malignancy on Immune Checkpoint Inhibitors},
journal = {Journal of the American Heart Association},
year = {2026},
doi = {10.1161/jaha.125.041163}
}
EUVIMED